Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Actinium Pharmaceuticals Inc 100 Park Ave. 23rd Floor NEW YORK NY 10017 USA

www.actiniumpharma.com P: 646-677-3870

Description:

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended to selectively deplete a patient's disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Their lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The SI

Key Statistics

Overview:

Market Capitalization, $K 260,601
Enterprise Value, $K 183,921
Shares Outstanding, K 29,783
Annual Sales, $ 80 K
Annual Net Income, $ -48,820 K
Last Quarter Sales, $ 80 K
Last Quarter Net Income, $ -9,320 K
EBIT, $ -51,990 K
EBITDA, $ -51,200 K
60-Month Beta 0.08
% of Insider Shareholders 4.00%
% of Institutional Shareholders 27.50%
Float, K 28,592
% Float 96.00%
Short Volume Ratio 0.40

Growth:

1-Year Return -0.11%
3-Year Return 22.91%
5-Year Return 10.54%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 72.31%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.31 on 04/26/24
Latest Earnings Date 05/20/24
Earnings Per Share ttm -1.83
EPS Growth vs. Prev Qtr 6.06%
EPS Growth vs. Prev Year 27.91%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 08/11/20

ATNM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -105.04%
Return-on-Assets % -51.93%
Profit Margin % -61,025.00%
Debt/Equity 0.00
Price/Sales 2,860.64
Price/Cash Flow N/A
Price/Book 5.23
Book Value/Share 1.31
Interest Coverage -2.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar